Allogene Therapeutics (ALLO) EBIT Margin: 2021-2025
Historic EBIT Margin for Allogene Therapeutics (ALLO) over the last 5 years, with Sep 2025 value amounting to 13,052.62%.
- Allogene Therapeutics' EBIT Margin fell 5872138.00% to 13,052.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 26,975.21%, marking a year-over-year decrease of 82393336.00%. This contributed to the annual value of -1,241,813.64% for FY2024, which is 89682732.00% down from last year.
- Allogene Therapeutics' EBIT Margin amounted to 13,052.62% in Q3 2025, which was down 38.43% from 21,201.12% recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' EBIT Margin ranged from a high of 74,679.01% in Q4 2024 and a low of -405,280.95% during Q4 2023.
- For the 3-year period, Allogene Therapeutics' EBIT Margin averaged around -147,978.38%, with its median value being -136,646.42% (2023).
- Per our database at Business Quant, Allogene Therapeutics' EBIT Margin tumbled by 37,075,226bps in 2022 and then spiked by 47,995,996bps in 2024.
- Over the past 5 years, Allogene Therapeutics' EBIT Margin (Quarterly) stood at 2.26% in 2021, then crashed by 37,075,226bps to -370,750.00% in 2022, then tumbled by 3,453,095bps to -405,280.95% in 2023, then spiked by 47,995,996bps to 74,679.01% in 2024, then plummeted by 5,872,138bps to 13,052.62% in 2025.
- Its EBIT Margin stands at 13,052.62% for Q3 2025, versus 21,201.12% for Q2 2025 and 43,460.67% for Q1 2025.